Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Executives On The Move: Bio/Med Changes Made From Lilly And Amgen, And A Step Up R&D Ladder At Daiichi Sankyo

Executive Summary

Eli Lilly & Co’s Biology VP takes on SVP, Discovery role at gene regulatory mechanism firm Fulcrum Therapeutics, and Amgen Med Affairs exec becomes CMO at Matinas BioPharma Holdings. At Daiichi Sankyo, R&D leader steps up to Global Head, R&D position.

You may also be interested in...



AstraZeneca And Galapagos Shine At The 15th Annual Scrip Awards

The pharma, biotech and allied industries came together in London on 4 December to celebrate another year of achievement at the 15th Annual Scrip Awards, hosted by the broadcaster Fiona Bruce.

Publisher's Spotlight: Scrip Awards Announces 2019 Finalists

We are delighted to announce the shortlist for the 15th Annual Scrip Awards.

Juvenescence Raises $100M To Advance Anti-Aging Programs

The financing, which brings the total raised by Juvenescence to $165m, comes as longevity R&D programs supported by the company move towards human testing.

Topics

UsernamePublicRestriction

Register

SC124853

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel